Strahlentherapie und Onkologie最新文献

{"title":"Multicenter multiplatform pattern-of-practice analysis of single-isocenter multitarget stereotactic radiosurgery.","authors":"Benedikt Thomann, Tobias Fechter, Johannes Fischer, Armin Runz, Julian Roers, Ute Ludwig, Melanie Grehn, Maximilian Grohmann, Christian Ziemann, Michael Judge, Wolfgang Baus, Michelle Grahle, Matthias Walke, Bastian Bathen, Janett Köhn, Paul Käthner, Maya Shariff, Rebecca Matthis, Jens Fleckenstein, Sascha Großmann, Tino Streller, Simon Howitz, Marlen Priegnitz, Rocco Weigel, Peter Winkler, Oliver Blanck, Daniela Schmitt, Jurgen Beck, Marcia Machein, Evangelos Pappas, Ilinca Popp, Michael Reiner, Christian P Karger, Christos Moustakis, Michael Bock, Anca-Ligia Grosu, Dimos Baltas","doi":"10.1007/s00066-025-02424-w","DOIUrl":"10.1007/s00066-025-02424-w","url":null,"abstract":"<p><strong>Purpose: </strong>Single-isocenter multitarget stereotactic radiosurgery (SIMT SRS) offers enhanced clinical efficiency for treating multiple brain metastases. However, it introduces additional uncertainties, such as off-center dose and beam profile inaccuracies, as well as quality assurance (QA) challenges, complicating its implementation. This study aims to evaluate different SIMT SRS approaches.</p><p><strong>Methods: </strong>We collected and analyzed SIMT SRS protocol and infrastructure parameters from 23 radiotherapy centers across Germany, Austria, and Switzerland, encompassing immobilization systems, computed tomography (CT) protocols, linear accelerators, treatment planning systems, beam configurations, imaging techniques, and QA practices. Consensus, deviations, and compliance with current guidelines were assessed. Subsequent studies will include on-site measurements, evaluation of treatment plan quality and delivery accuracy, and correlation of these findings with the analyzed protocols to identify potential links between protocol parameters and clinical outcomes.</p><p><strong>Results: </strong>There is consensus (at least 80% agreement) for a CT slice thickness of ≤ 1 mm, the need for six-degree-of-freedom patient setup correction, and noncoplanar treatment. There is notable variability for intrafraction imaging (used by 70%), minimum accepted planning target volume diameter (ranging from 2-10 mm), SRS QA, and general plan parameters, such as photon energy and number of treatment fields. There is also high variability in employed linear accelerator models and treatment planning systems.</p><p><strong>Conclusion: </strong>These findings highlight a lack of standardization in SIMT SRS practices. Combined with future measurements correlating protocols to treatment quality, our study will provide a foundation for recommendations to support the safe and standardized implementation of SIMT SRS.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"953-962"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review.","authors":"Clara Grinzinger, Georg Stüben, Maria Neu, Anna Rubeck, Stefan Schiele, Lars Behrens, Klaus-Henning Kahl","doi":"10.1007/s00066-025-02416-w","DOIUrl":"10.1007/s00066-025-02416-w","url":null,"abstract":"<p><strong>Purpose: </strong>With increasing use of human epithelial growth factor receptor two (HER2)-targeted therapies, outcomes for numerous breast cancer patients have improved. Nevertheless, patients with HER2-positive tumours face a comparatively heightened risk for developing brain metastases (BM), which are often treated with stereotactic radiosurgery (SRS). Radionecrosis represents one of the clinically most significant adverse events of SRS. However, a knowledge gap remains regarding the effects of concurrent use of HER2-targeted therapies with SRS on development of radionecrosis, given conflicting findings in existing studies.</p><p><strong>Methods: </strong>This systematic review was conducted in May 2024 through a search across electronic databases PubMed/MEDLINE and Cochrane library and was supplemented by citation searching and an artificial intelligence (AI) search.</p><p><strong>Results: </strong>The literature search yielded 194 articles. After applying eligibility criteria, a total of 13 studies with 3219 patients total were included, with approximately 270 patients in the topic-relevant subgroup. Investigated substances vary in different publications and include HER2 antibodies, antibody-drug conjugates (ADCs), such as trastuzumab emtansine (T-DM1), and kinase inhibitors. Four of six studies on ADCs demonstrated a higher risk for radionecrosis with concurrent administration. Two studies on lapatinib found no significant effects, as did as most studies investigating mainly HER2 antibodies. One publication reported an even lower risk for radionecrosis (RN) with concurrent use of HER2/EGFR tyrosine kinase inhibitors (TKIs).</p><p><strong>Conclusion: </strong>While concurrent use of T‑DM1/ADCs seems associated to elevated radionecrosis risk, an ambiguous situation for other substances persists. Heterogenous study designs with varying substances, definitions of concurrent use, and radionecrosis parameters must be considered. Included studies are partly limited by sample size and retrospective study design. Therefore, clinical implications remain difficult to claim; further research on this topic is needed.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"863-873"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-SRS haemorrhage and oncological outcome of patients with melanoma brain metastases undergoing stereotactic radiotherapy.","authors":"Christina Schröder, Joseph Sia, Claire Phillips, Michelle Li, Lavinia Spain, Neda Haghighi","doi":"10.1007/s00066-025-02393-0","DOIUrl":"10.1007/s00066-025-02393-0","url":null,"abstract":"<p><strong>Purpose: </strong>Melanoma brain metastases (MBM) pose significant challenges in management due to their propensity for intralesional haemorrhage. This retrospective analysis aims to evaluate the oncological outcomes and incidence of haemorrhage following stereotactic radiosurgery (SRS) in patients with MBM.</p><p><strong>Methods: </strong>Patients who received SRS for MBM between 10/2020 and 01/2023 were included. The primary objective was to analyse the incidence of post-SRS haemorrhage. Secondary objectives included oncological outcomes and radiation necrosis. Descriptive statistics and Kaplan-Meier curves were used. Uni- and multivariate statistics analysed factors influencing the incidence of haemorrhage and local failure.</p><p><strong>Results: </strong>A total of 69 patients with 250 MBMs were included; 65 metastases (26.0%) showed signs of haemorrhage at the time of SRS. Post-SRS, new or increased haemorrhage occurred in 13.2% of treated metastases, primarily within the first year. The 1‑ and 2‑year local control rates were 76.6% each. The 1‑ and 2‑year distant brain failure rates were 40.6% and 34.1% and median overall survival was 14.3 months. For the haemorrhage endpoint, the presence of initial haemorrhage, biologically effective prescription dose, lesion diameter and the planning target volume margin were statistically significant in univariate analysis, and initial haemorrhage remained significant in multivariate analysis. For local control, significant factors in uni- and multivariate analysis were the status of extracranial disease, post-SRS haemorrhage and the use of anticoagulation.</p><p><strong>Conclusion: </strong>Stereotactic radiosurgery is an effective treatment for MBM with good local control. The risk of haemorrhage after SRS is low and strongly associated with the presence of pre-SRS haemorrhage. Patients are at risk of developing haemorrhage in new, formerly untreated metastases.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"886-893"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults.","authors":"Alper Kahvecioglu, Mustafa Cengiz, Guzide Burca Aydin, Mustafa Tezer Kutluk, Gokcen Coban Cifci, Gozde Yazici","doi":"10.1007/s00066-025-02394-z","DOIUrl":"10.1007/s00066-025-02394-z","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to assess oncological outcomes in children and young adults with diffuse infiltrative pontine glioma (DIPG) who have progressed after initial radiotherapy (RT), with an emphasis on the role of re-irradiation.</p><p><strong>Methods: </strong>Data from 33 patients aged 25 years or younger with progressive disease after initial RT were retrospectively analyzed.</p><p><strong>Results: </strong>The median age at diagnosis was 8 years (range 4-24 years), and the median initial RT dose was 54 Gy (range 39-54 Gy). The median time between initial RT and progression was 8 months (range 3-40 months). In addition to systemic therapy, 15 patients (46%) received re-irradiation due to progression, with a median dose of 23.4 Gy (range 19.8-36 Gy), while 18 patients (54%) were treated with systemic therapy alone. In patients who received re-irradiation after progression, the 1‑year post-progression overall survival (OS) was significantly higher compared to those treated with systemic therapy alone (27% vs. 0%, p = 0.01). Among the 15 re-irradiated patients, 9 out of 12 with available data (75%) showed improvement in neurological symptoms following re-irradiation. No patient exhibited acute or late RT-related ≥ grade 3 toxicity.</p><p><strong>Conclusion: </strong>Palliative re-irradiation in children and young adults with progressive DIPG after initial RT provides an approximately 3‑month OS benefit and clinical improvement without significant toxicity and should be considered as a standard-of-care approach.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"894-902"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[First-generation TKI and simultaneous thoracic radiotherapy for EGFR-mutated metastatic Non-Small Cell Lung Cancer (NSCLC): a promising new approach?]","authors":"Korneel Hartong, Fabian Weykamp","doi":"10.1007/s00066-025-02428-6","DOIUrl":"10.1007/s00066-025-02428-6","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"973-975"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advantages of 3D printed patient-individual moulds in brachytherapy for facial skin cancer.","authors":"Jörg Licher, Julia Achenbach, Janett Köhn, Markus Diefenhardt, Maximilian Fleischmann, Claus Rödel, Nikolaos Tselis, Ulla Ramm, Christian Scherf","doi":"10.1007/s00066-025-02372-5","DOIUrl":"10.1007/s00066-025-02372-5","url":null,"abstract":"<p><strong>Purpose: </strong>Facial skin cancer of 42 elderly frail patients was treated with individualised 3D-printed mould applicators for high-dose-rate (HDR) brachytherapy. The dosimetric outcome was compared to conventionally manufactured individual moulds used before.</p><p><strong>Methods: </strong>Tumour-adapted HDR brachytherapy source paths were pre-planned and dosimetrically optimised in the brachytherapy treatment planning system (TPS) using computed tomography (CT) data and considered in the design of the patient-individual moulds. Dosimetric outcome for the planning target volumes and organs at risk were statistically evaluated and compared for pre-planning, final clinical treatment planning with TG-43 formalism and retrospective tissue, material and CT density related TG-186 calculations.</p><p><strong>Results: </strong>Pre-planning allows reliable brachytherapy source paths design to achieve intended dosimetric clinical goals. The 3D-printed patient-specific moulds show a clear advantage in the dosimetric coverage of the target volume (improving D₉₀ from 98.3% to 104.3%) and the protection of the relevant organs at risk (reduction up to 30% of maximum Dose). With the 3D-printed moulds only minor deviations were observed for TG-43 and TG-186 dose recalculations of the treated plans.</p><p><strong>Conclusion: </strong>Customised 3D printed moulds offer a safe and efficient technique to treat facial skin cancer in critical locations and complex clinical situations with HDR brachytherapy. The two-step planning process results in reliable PTV dose coverage and efficient sparing of eye lenses and eyeballs. Dosimetric outcome and interfractional position reproducibility with 3D printed moulds were superior to conventionally manufactured facial moulds with respect to the clinical goals.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"940-952"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of surface tracking recordings to identify pitfalls during surface-guided radiotherapy.","authors":"G Klumpp, S Baumbach, N Wegner, P Freislederer, L Wagner, K P Aninditha, T Ellethy, M Münter","doi":"10.1007/s00066-024-02331-6","DOIUrl":"10.1007/s00066-024-02331-6","url":null,"abstract":"<p><strong>Objective: </strong>The precise daily positioning of patients during radiation therapy determines the quality of the entire treatment. To avoid additional radiation exposure from regular cone-beam CT (CBCT) scans, surface-guided radiotherapy systems (SGRT) are increasingly used. The aim of this prospective clinical study was to evaluate the advantages, feasibility, and pitfalls of SGRT using the surface tracking recorder prototype of the camera component of ExacTrac Dynamic (Brainlab AG, Munich, Germany). This system combines both surface-based imaging technology and a thermographic camera that records patients via thermal imaging to accurately measure patient geometry.</p><p><strong>Methods: </strong>The surfaces of patients with various tumor entities and therefore different regions of interest (ROIs) were recorded with the surface camera during positioning and throughout treatment. Subsequently, these surface camera datasets were analyzed to compare the accuracy of patient positioning with the current treatment standard (X-ray-based IGRT). The camera components were used only as an imaging tool and not to correct any deviations. For evaluation of typical pitfalls, errors > 5 mm for extracranial indications and > 2 mm for cranial indications were analyzed using parameters extracted from the surface recordings and the corresponding CBCT shifts.</p><p><strong>Results: </strong>In total, 162 displacement vector datasets for 130 patients were generated and evaluated. The smallest deviations were found in the head and neck regions (mean deviation 1.9 mm/0.8°). The largest mean translational deviation (4.8 mm) and mean rotational deviation (1.1°) were found in the pelvic area. In all regions, most datasets showed clinically acceptable deviations; however, large outliers were observed in some measurements, particularly longitudinally. These outliers are of special interest because they may indicate mistakes in the use of SGRT, and they were therefore analyzed separately in detail. Several reasons for the outliers were identified, and potential solutions to avoid these pitfalls are presented.</p><p><strong>Conclusion: </strong>This observational study demonstrated the advantages and pitfalls of SGRT by using the surface tracking recorder prototype of the camera component of ExacTrac Dynamic. These pitfalls can be avoided through thorough application of SGRT. This study may serve as a practical guide for clinicians already using or introducing SGRT for patient positioning.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"930-939"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceftriaxone has a neuroprotective effect in a whole-brain irradiation-induced neurotoxicity model by increasing GLT-1 and reducing oxidative stress.","authors":"Nilsu Cini, Özüm Atasoy, Yigit Uyanikgil, Gökhan Yaprak, Mümin Alper Erdoğan, Oytun Erbas","doi":"10.1007/s00066-025-02405-z","DOIUrl":"10.1007/s00066-025-02405-z","url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced brain injury is a prominent side effect of whole-brain irradiation (IR) due to triggered oxidative and inflammatory processes, often resulting in severe and debilitating cognitive dysfunction and neuronal damage. The development of persistent oxidative stress results from radiation-induced reactive oxygen species. Another result is the initiation of glutamate excitotoxicity, which is closely associated with changes in glutamate levels. Elevated release or reduced glutamate uptake disrupts neuronal homeostasis, leading to oxidative stress, mitochondrial dysfunction, and neuroinflammation. The neuroprotective and antioxidant properties of ceftriaxone (CTX) have been linked to its ability to reduce glutamate excitotoxicity, inflammation, and to modulate oxidative stress.</p><p><strong>Materials and methods: </strong>Twenty-one female Wistar rats were included in the study, and 14 of them underwent whole-brain IR with a single dose of 20 Gy on day 7. Saline and CTX applications continued for 21 days. The animals were divided into three groups: group 1: normal control; group 2: IR + saline; and group 3: IR + CTX. To compare the groups, a one-way analysis of variance (ANOVA) statistical test was employed, with a significance threshold set at p < 0.05.</p><p><strong>Results: </strong>Ceftriaxone treatment had a positive impact on the results of various assessments, e.g., behavioral tests including the three-chamber sociability test, the open-field test, and passive avoidance learning. It also led to increased counts of hippocampal CA1, CA3, and Purkinje neurons as well as elevated brain levels of brain-derived neurotrophic factor (BDNF), glutamate transporter 1 (GLT-1), and superoxide dismutase (SOD) activity. Conversely, CTX reduced the glial fibrillary acidic protein (GFAP) immunostaining index as well as brain levels of malondialdehyde (MDA) and tumor necrosis factor alpha (TNF-α).</p><p><strong>Conclusion: </strong>Ceftriaxone demonstrated promising effectiveness in mitigating radiation-induced neurocognitive impairments and the deterioration of social memory capacity. This effect is achieved by reducing neuronal loss, oxidative stress, and neuroinflammation in irradiated rat brains. Furthermore, the application of CTX facilitated removal of excess glutamate from synapses, thus preventing glutamate excitotoxicity and protecting neurons from excitotoxic cell death.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"903-919"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CyberKnife radiation therapy for malignant myopericytoma in a pediatric patient: a case report and review of the literature.","authors":"Bence Bukovszky, Júlia Vízkeleti, Levente Jánváry, Gábor Szarvas, Luca Felkai, Rita Bánusz, Edit Varga, Zoltán Sápi, Tibor Major, Monika Csóka","doi":"10.1007/s00066-025-02413-z","DOIUrl":"10.1007/s00066-025-02413-z","url":null,"abstract":"<p><strong>Background: </strong>Malignant myopericytoma is a very rare malignant soft tissue tumor which usually develops during adulthood. It has a very poor prognosis due to its aggressive nature and frequent distant metastases.</p><p><strong>Methods: </strong>In our case report, we present a 17-month-old girl with malignant myopericytoma who was successfully treated using CyberKnife (Accuray; Sunnyvale, CA, USA) stereotactic radiotherapy.</p><p><strong>Results: </strong>A rare localization of the tumor caused significant challenges during the course of treatment. Radical surgical resection was not achievable due to the tumor's location in the inner ear; therefore chemotherapy was initially given to the patient. However, due to the fast progression of the tumor during chemotherapy, we decided to use CyberKnife stereotactic radiosurgery (SRS; 5 fractions of 7 Gy) in order to prevent further invasion of the surrounding tissues. During SRS, tumor growth stopped and the tumor then gradually regressed. Since completion of treatment (currently almost 5 years) our patient has been in complete remission without any significant side effects of the radiation therapy.</p><p><strong>Conclusion: </strong>In our recent experience, systemic chemotherapy combined with CyberKnife SRS proved to be effective in a patient with a rare malignant myopericytoma.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"963-970"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Less is more: dose de-escalation in early anal cancer-Clinical and functional aspects of quality of life from the PLATO-ACT4 trial].","authors":"L Völler, E Fokas, C Rödel, D Martin","doi":"10.1007/s00066-025-02430-y","DOIUrl":"10.1007/s00066-025-02430-y","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"976-978"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}